Accounting Changes and Error Corrections (Details) - USD ($)	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2021
Accounting Changes and Error Corrections [Abstract]
Other Accrued Liabilities		$ 553,000,000	$ 484,000,000				$ 553,000,000				$ 646,000,000	$ 646,000,000
Total current liabilities	$ 1,487,000,000	1,552,000,000	969,000,000				1,552,000,000		$ 1,487,000,000		1,098,000,000	1,098,000,000
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other Accrued Liabilities		553,000,000	484,000,000				553,000,000				646,000,000	646,000,000
Total current liabilities	1,487,000,000	1,552,000,000	969,000,000				1,552,000,000		1,487,000,000		1,098,000,000	1,098,000,000
Total liabilities	6,127,000,000	6,256,000,000	5,526,000,000				6,256,000,000		6,127,000,000		5,733,000,000	5,733,000,000
Retained earnings (Accumulated Deficit)		599,000,000					599,000,000
Accumulated deficit	372,000,000		518,000,000						372,000,000		518,000,000	518,000,000
Equity, Attributable to Parent	4,703,000,000	4,892,000,000	4,680,000,000				4,892,000,000		4,703,000,000		4,775,000,000	4,775,000,000
Prepaid expenses and other	693,000,000	715,000,000	633,000,000				715,000,000		693,000,000		626,000,000	626,000,000
Assets, Current	2,738,000,000	2,919,000,000	2,699,000,000				2,919,000,000		2,738,000,000		2,917,000,000	2,917,000,000
Deferred Income Tax Assets, Net	42,000,000								42,000,000		49,000,000
Assets	10,830,000,000	11,148,000,000	10,206,000,000				11,148,000,000		10,830,000,000		10,508,000,000	10,508,000,000
Liabilities and Equity	10,830,000,000	11,148,000,000	10,206,000,000				11,148,000,000		10,830,000,000		10,508,000,000	10,508,000,000
Net revenue	1,037,000,000		1,015,000,000	$ 1,273,000,000					3,208,000,000	$ 3,515,000,000	4,802,000,000
Gross margin	180,000,000		251,000,000	423,000,000					825,000,000	1,152,000,000	1,614,000,000
Operating earnings	(235,000,000)		53,000,000	211,000,000					(37,000,000)	510,000,000	730,000,000
Deferred Tax Liabilities, Gross	119,000,000	216,000,000	208,000,000				216,000,000		119,000,000		197,000,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(282,000,000)		(4,000,000)	176,000,000					(165,000,000)	394,000,000	579,000,000
Income tax expense(benefit)	(55,000,000)	34,000,000	1,000,000	35,000,000					(19,000,000)	63,000,000	80,000,000
Net earnings/(loss)	(227,000,000)	$ 80,000,000	$ (5,000,000)	141,000,000					(146,000,000)	331,000,000	499,000,000
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic	0			0					0	(15,000,000)
Net Income (Loss) Available to Common Stockholders, Basic	$ (227,000,000)			$ 141,000,000					$ (146,000,000)	$ 316,000,000	$ 483,000,000
Earnings Per Share, Basic	$ (1.26)	$ 440,000	$ (0.03)	$ 0.78					$ (0.81)	$ 1.81	$ 2.74
Earnings Per Share, Diluted	$ (1.26)		$ (0.03)	$ 0.78					$ (0.81)	$ 1.79	$ 2.73
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ (200,000,000)	$ 199,000,000	$ (125,000,000)	$ 136,000,000					$ (120,000,000)	$ 298,000,000	$ 422,000,000
Net earnings/(loss)			(5,000,000)				75,000,000		(146,000,000)	331,000,000
Provision/(benefit) for deferred income taxes							12,000,000		69,000,000	(13,000,000)	(9,000,000)
Other assets/accrued liabilities, net — current and non-current			(150,000,000)				(174,000,000)		(245,000,000)	(293,000,000)	(423,000,000)
Net cash provided by operating activities									58,000,000	370,000,000
Net Cash Provided by (Used in) Investing Activities									(834,000,000)	(1,490,000,000)
Net Cash Provided by (Used in) Financing Activities									572,000,000	1,030,000,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect									(197,000,000)	(110,000,000)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	252,000,000			786,000,000					252,000,000	786,000,000	449,000,000		$ 896,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities										362,000,000
Share issuances related to stock-based compensation									35,000,000	42,000,000
Cash paid, in lieu of equity, for tax withholding										9,000,000
Proceeds from Stock Options Exercised									(4,000,000)	(21,000,000)
APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition	2,000,000			3,000,000					9,000,000
Dividends, Preferred Stock										6,000,000
Other Comprehensive Income (Loss), Net of Tax	27,000,000			(5,000,000)					26,000,000	(33,000,000)
Inventories	744,000,000								744,000,000		702,000,000
Inter-segment revenue elimination	(1,000,000)	(1,000,000)	0	(1,000,000)	$ (1,000,000)	$ (1,000,000)	(1,000,000)	$ (2,000,000)	(2,000,000)	(3,000,000)
Revenue		1,149,000,000	1,022,000,000		1,217,000,000	1,025,000,000	2,171,000,000	2,242,000,000
Cost of sales	857,000,000			850,000,000					2,383,000,000	2,363,000,000
Deferred Tax Liabilities, Tax Deferred Income												197,000,000
Total liabilities	6,127,000,000	6,256,000,000	5,526,000,000				6,256,000,000		6,127,000,000		5,733,000,000	5,733,000,000
Accumulated deficit	372,000,000		518,000,000						372,000,000		518,000,000	518,000,000
Equity, Attributable to Parent	4,703,000,000	4,892,000,000	4,680,000,000				4,892,000,000		4,703,000,000		4,775,000,000	4,775,000,000
Inventories	744,000,000								744,000,000		702,000,000
Biologics
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Assets	5,904,000,000								5,904,000,000		5,770,000,000
Net revenue	475,000,000			700,000,000					1,578,000,000	1,889,000,000
Revenue		580,000,000	523,000,000		641,000,000	548,000,000	1,103,000,000	1,189,000,000
Biologics | Manufacturing & Commercial Product Supply
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	133,000,000			200,000,000					303,000,000	503,000,000
Revenue		75,000,000	94,000,000		169,000,000	134,000,000	169,000,000	303,000,000
Biologics | Development Services
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	342,000,000			500,000,000					1,275,000,000	1,386,000,000
Revenue		505,000,000	429,000,000		472,000,000	414,000,000	934,000,000	886,000,000
PharmaConsumerHealth
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Assets	4,847,000,000								4,847,000,000		4,356,000,000
Net revenue	563,000,000			574,000,000					1,632,000,000	1,629,000,000
Revenue		570,000,000	499,000,000		577,000,000	478,000,000	1,069,000,000	1,055,000,000
PharmaConsumerHealth | Manufacturing & Commercial Product Supply
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	349,000,000			368,000,000					1,027,000,000	1,042,000,000
Revenue		364,000,000	314,000,000		381,000,000	293,000,000	678,000,000	674,000,000
PharmaConsumerHealth | Development Services
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	214,000,000			206,000,000					605,000,000	587,000,000
Revenue		206,000,000			196,000,000	185,000,000	391,000,000	381,000,000
Total Catalent before inter-segment revenue elimination
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	1,038,000,000			1,274,000,000					3,210,000,000	3,518,000,000
Revenue		1,150,000,000	1,022,000,000		1,218,000,000	1,026,000,000	2,172,000,000	2,244,000,000
Total Catalent before inter-segment revenue elimination | Manufacturing & Commercial Product Supply
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	482,000,000			568,000,000					1,330,000,000	1,545,000,000
Revenue		439,000,000	408,000,000		550,000,000	427,000,000	847,000,000	977,000,000
Total Catalent before inter-segment revenue elimination | Development Services
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 556,000,000			$ 706,000,000					$ 1,880,000,000	$ 1,973,000,000
Revenue		711,000,000			$ 668,000,000	$ 599,000,000	1,325,000,000	$ 1,267,000,000
Previously Reported
Accounting Changes and Error Corrections [Abstract]
Other Accrued Liabilities		527,000,000	458,000,000				527,000,000				620,000,000	620,000,000
Total current liabilities		1,526,000,000	943,000,000				1,526,000,000				1,072,000,000	1,072,000,000
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other Accrued Liabilities		527,000,000	458,000,000				527,000,000				620,000,000	620,000,000
Total current liabilities		1,526,000,000	943,000,000				1,526,000,000				1,072,000,000	1,072,000,000
Total liabilities		6,235,000,000	5,505,000,000				6,235,000,000				5,712,000,000	5,712,000,000
Accumulated deficit		619,000,000	538,000,000				619,000,000				538,000,000	538,000,000
Equity, Attributable to Parent		4,912,000,000	4,700,000,000				4,912,000,000				4,795,000,000	4,795,000,000
Prepaid expenses and other		714,000,000	632,000,000				714,000,000				625,000,000	625,000,000
Assets, Current		2,918,000,000	2,698,000,000				2,918,000,000				2,916,000,000	2,916,000,000
Assets		11,147,000,000	10,205,000,000				11,147,000,000				10,507,000,000	10,507,000,000
Liabilities and Equity		11,147,000,000	10,205,000,000				11,147,000,000				10,507,000,000
Net revenue			1,022,000,000				2,171,000,000				4,828,000,000
Gross margin			258,000,000				645,000,000				1,640,000,000
Operating earnings			60,000,000				198,000,000				756,000,000
Deferred Tax Liabilities, Gross		221,000,000	214,000,000				221,000,000				202,000,000	202,000,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest			3,000,000				117,000,000				605,000,000
Income tax expense(benefit)		33,000,000	3,000,000				36,000,000				86,000,000
Net earnings/(loss)		$ 81,000,000	$ 0				$ 81,000,000				519,000,000
Net Income (Loss) Available to Common Stockholders, Basic											$ 503,000,000
Earnings Per Share, Basic		$ 450,000	$ 0				$ 450,000				$ 2.85
Earnings Per Share, Diluted			$ 0				$ 450,000				$ 2.84
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest		$ 200,000,000	$ (120,000,000)				$ 80,000,000				$ 442,000,000
Net earnings/(loss)			0				81,000,000
Provision/(benefit) for deferred income taxes							13,000,000				14,000,000
Other assets/accrued liabilities, net — current and non-current			(155,000,000)				(181,000,000)				(448,000,000)
Total liabilities		6,235,000,000	5,505,000,000				6,235,000,000				5,712,000,000	5,712,000,000
Accumulated deficit		619,000,000	538,000,000				619,000,000				538,000,000	538,000,000
Equity, Attributable to Parent		4,912,000,000	4,700,000,000				4,912,000,000				4,795,000,000	4,795,000,000
Restatement Adjustment
Accounting Changes and Error Corrections [Abstract]
Other Accrued Liabilities		26,000,000	26,000,000				26,000,000				26,000,000	26,000,000
Total current liabilities		26,000,000	26,000,000				26,000,000				26,000,000	26,000,000
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other Accrued Liabilities		26,000,000	26,000,000				26,000,000				26,000,000	26,000,000
Total current liabilities		26,000,000	26,000,000				26,000,000				26,000,000	26,000,000
Total liabilities		21,000,000	21,000,000				21,000,000				21,000,000	21,000,000
Accumulated deficit		(20,000,000)	(20,000,000)				(20,000,000)				(20,000,000)	(20,000,000)
Equity, Attributable to Parent		(20,000,000)	(20,000,000)				(20,000,000)				(20,000,000)	(20,000,000)
Prepaid expenses and other		1,000,000	1,000,000				1,000,000				1,000,000	1,000,000
Assets, Current		1,000,000	1,000,000				1,000,000				1,000,000	1,000,000
Assets		1,000,000	1,000,000				1,000,000				1,000,000	1,000,000
Liabilities and Equity		1,000,000	1,000,000				1,000,000				1,000,000
Net revenue			(7,000,000)				(7,000,000)				(26,000,000)
Gross margin			(7,000,000)				(7,000,000)				(26,000,000)
Operating earnings			(7,000,000)				(7,000,000)				(26,000,000)
Income tax expense(benefit)		1,000,000	(2,000,000)				(1,000,000)				(6,000,000)
Net earnings/(loss)		$ (1,000,000)	$ (5,000,000)				$ (6,000,000)				(20,000,000)
Net Income (Loss) Available to Common Stockholders, Basic											$ (20,000,000)
Earnings Per Share, Basic		$ (10,000.00)	$ (0.03)				$ (30,000.00)				$ (0.11)
Earnings Per Share, Diluted			$ (0.03)				$ (30,000.00)				$ (0.11)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest		$ (1,000,000)	$ (5,000,000)								$ (20,000,000)
Net earnings/(loss)			(5,000,000)				$ (6,000,000)
Provision/(benefit) for deferred income taxes							(1,000,000)				(5,000,000)
Other assets/accrued liabilities, net — current and non-current			5,000,000				7,000,000				25,000,000
Total liabilities		21,000,000	21,000,000				21,000,000				21,000,000	21,000,000
Accumulated deficit		(20,000,000)	(20,000,000)				(20,000,000)				(20,000,000)	(20,000,000)
Equity, Attributable to Parent		(20,000,000)	(20,000,000)				(20,000,000)				(20,000,000)	(20,000,000)
Revision of Prior Period, Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Deferred Tax Liabilities, Gross		$ (5,000,000)	(5,000,000)				(5,000,000)				(5,000,000)	$ (5,000,000)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest			$ (7,000,000)				$ (7,000,000)				$ (26,000,000)